The Experts below are selected from a list of 1146 Experts worldwide ranked by ideXlab platform
Amir Zait - One of the best experts on this subject based on the ideXlab platform.
-
an artificial intelligence assisted diagnostic platform for rapid near patient hematology
American Journal of Hematology, 2021Co-Authors: Neta Bachar, Dana Benbassat, David Brailovsky, Yochay Eshel, Dan Gluck, Daniel Levner, Sarah Levy, Sharon Pecker, Evgeny Yurkovsky, Amir ZaitAbstract:Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19-parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-fingerprick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks.
-
an artificial intelligence assisted diagnostic platform for rapid near patient hematology
American Journal of Hematology, 2021Co-Authors: Neta Bachar, Dana Benbassat, David Brailovsky, Yochay Eshel, Dan Gluck, Daniel Levner, Sarah Levy, Sharon Pecker, Evgeny Yurkovsky, Amir ZaitAbstract:Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO® (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19 parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-finger-prick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks. This article is protected by copyright. All rights reserved.
-
an artificial intelligence assisted diagnostic platform for rapid near patient hematology
medRxiv, 2021Co-Authors: Neta Bachar, Dana Benbassat, David Brailovsky, Yochay Eshel, Dan Gluck, Daniel Levner, Sarah Levy, Sharon Pecker, Evgeny Yurkovsky, Amir ZaitAbstract:Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO® (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19 parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-finger-prick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks. One Sentence Summary We present a novel diagnostic platform based on artificial intelligence-assisted image analysis that is capable of performing rapid complete blood count from venous, capillary, and finger-prick samples in near-patient settings.
Linda M. Sandhaus - One of the best experts on this subject based on the ideXlab platform.
-
Is the Hemocytometer Obsolete for Body Fluid Cell Counting
American journal of clinical pathology, 2016Co-Authors: Linda M. SandhausAbstract:Automated body fluid (BF) cell counts performed on hematology analyzers have been steadily replacing manual hemocytometer (counting chamber) cell counts in clinical laboratories. Hematology analyzers with dedicated BF modes are capable of producing an RBC count, total nucleated cell (TNC) count, WBC count, and a limited WBC differential count. Distinguishing TNCs from WBCs is particularly useful for serous fluids, where body cavity lining cells may be present in significant numbers and can interfere with the accuracy of manual WBC counts if they are not excluded. Although lining cells rarely interfere with WBC counts in cerebrospinal fluid (CSF), the extremely low CSF WBC concentrations relative to blood have limited the use of automated hematology analyzers for CSF cell counts. Achieving the accuracy and precision required to reliably distinguish pathologic CSF specimens from normal samples has posed a challenge to automated hematology analyzer manufacturers. In this issue, Fleming et al1 present an evaluation of a new high-sensitivity analysis (hsA) BF mode on the Sysmex XN hematology analyzer (Sysmex, Kobe, Japan) for CSF cell counts. The hsA BF mode is not yet commercially available but can be accessed for research purposes on the XN analyzers. Their results suggest that Sysmex has met the challenge of automated enumeration of WBCs and RBCs in CSF samples. The limit of quantitation (LoQ) expresses the precision (functional sensitivity) of the analyzer and is useful for comparing the accuracy of different analyzers for low cell counts, such as exist in CSF.2 These investigators defined LoQ as the lowest cell count that can be obtained … Corresponding author: Linda M. Sandhaus, MD, University Hospitals Case Medical Center, 11100 Euclid Ave, Cleveland, OH 44106; Linda.Sandhaus{at}UHhospitals.org.
Neta Bachar - One of the best experts on this subject based on the ideXlab platform.
-
an artificial intelligence assisted diagnostic platform for rapid near patient hematology
American Journal of Hematology, 2021Co-Authors: Neta Bachar, Dana Benbassat, David Brailovsky, Yochay Eshel, Dan Gluck, Daniel Levner, Sarah Levy, Sharon Pecker, Evgeny Yurkovsky, Amir ZaitAbstract:Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19-parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-fingerprick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks.
-
an artificial intelligence assisted diagnostic platform for rapid near patient hematology
American Journal of Hematology, 2021Co-Authors: Neta Bachar, Dana Benbassat, David Brailovsky, Yochay Eshel, Dan Gluck, Daniel Levner, Sarah Levy, Sharon Pecker, Evgeny Yurkovsky, Amir ZaitAbstract:Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO® (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19 parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-finger-prick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks. This article is protected by copyright. All rights reserved.
-
an artificial intelligence assisted diagnostic platform for rapid near patient hematology
medRxiv, 2021Co-Authors: Neta Bachar, Dana Benbassat, David Brailovsky, Yochay Eshel, Dan Gluck, Daniel Levner, Sarah Levy, Sharon Pecker, Evgeny Yurkovsky, Amir ZaitAbstract:Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO® (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19 parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-finger-prick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks. One Sentence Summary We present a novel diagnostic platform based on artificial intelligence-assisted image analysis that is capable of performing rapid complete blood count from venous, capillary, and finger-prick samples in near-patient settings.
Hui Liu - One of the best experts on this subject based on the ideXlab platform.
-
quantitative determination of agglutination based on the automatic hematology analyzer and the clinical significance of the erythrocyte specific antibody
Clinica Chimica Acta, 2020Co-Authors: Nan Sheng, Lina Liu, Hui LiuAbstract:Abstract Objective The objective of this work was to explore the similarities and differences between the automatic hematology analyzer method and the traditional slide method in the detection of red blood cell (RBC) agglutination, and demonstrate that the automatic hematology analyzer is more intuitive and reliable for the detection of RBC agglutination. A further objective was to establish a new method to facilitate new ideas for clinical research. Methods Type A serum was selected and diluted 1:2, 1:4, 1:8, 1:16, and 1:32, to react with the type B cells and the normal saline group was used as the control group. An RBC count was performed using an automatic hematology analyzer, after incubation in a warm bath for 30 min. The degree of agglutination on the glass slide was also recorded. A positive serum of antinuclear antibody (ANA) was collected and RBC agglutination between RBC-O and ANA positive serum was determined using the automatic hematology analyzer method. Result The relationship between the results from the automatic hematology analyzer and the agglutination strength using the glass slide method was determined. There was a significant difference between the serum of ANA positive patients and the normal control group (P Conclusion A new method for detecting RBC agglutination using an automatic hematology analyzer has been established and is a valid tool for clinical research.
David Brailovsky - One of the best experts on this subject based on the ideXlab platform.
-
an artificial intelligence assisted diagnostic platform for rapid near patient hematology
American Journal of Hematology, 2021Co-Authors: Neta Bachar, Dana Benbassat, David Brailovsky, Yochay Eshel, Dan Gluck, Daniel Levner, Sarah Levy, Sharon Pecker, Evgeny Yurkovsky, Amir ZaitAbstract:Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19-parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-fingerprick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks.
-
an artificial intelligence assisted diagnostic platform for rapid near patient hematology
American Journal of Hematology, 2021Co-Authors: Neta Bachar, Dana Benbassat, David Brailovsky, Yochay Eshel, Dan Gluck, Daniel Levner, Sarah Levy, Sharon Pecker, Evgeny Yurkovsky, Amir ZaitAbstract:Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO® (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19 parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-finger-prick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks. This article is protected by copyright. All rights reserved.
-
an artificial intelligence assisted diagnostic platform for rapid near patient hematology
medRxiv, 2021Co-Authors: Neta Bachar, Dana Benbassat, David Brailovsky, Yochay Eshel, Dan Gluck, Daniel Levner, Sarah Levy, Sharon Pecker, Evgeny Yurkovsky, Amir ZaitAbstract:Hematology analyzers capable of performing complete blood count (CBC) have lagged in their prevalence at the point-of-care. Sight OLO® (Sight Diagnostics, Israel) is a novel hematological platform which provides a 19 parameter, five-part differential CBC, and is designed to address the limitations in current point-of-care hematology analyzers using recent advances in artificial intelligence (AI) and computer vision. Accuracy, repeatability, and flagging capabilities of OLO were compared with the Sysmex XN-Series System (Sysmex, Japan). Matrix studies compared performance using venous, capillary and direct-from-finger-prick blood samples. Regression analysis shows strong concordance between OLO and the Sysmex XN, demonstrating that OLO performs with high accuracy for all CBC parameters. High repeatability and reproducibility were demonstrated for most of the testing parameters. The analytical performance of the OLO hematology analyzer was validated in a multicenter clinical laboratory setting, demonstrating its accuracy and comparability to clinical laboratory-based hematology analyzers. Furthermore, the study demonstrated the validity of CBC analysis of samples collected directly from fingerpricks. One Sentence Summary We present a novel diagnostic platform based on artificial intelligence-assisted image analysis that is capable of performing rapid complete blood count from venous, capillary, and finger-prick samples in near-patient settings.
